Table 1.
Baseline patient characteristics.
| Roflumilast N = 23 | Placebo N = 23 | |
|---|---|---|
| Demographics | ||
| Age [years], median (IQR) | 38.0 (30.0, 43.0) | 39.0 (32.5, 50.0) |
| Men, n (%) | 15 (65) | 19 (83) |
| Caucasian, n (%) | 23 (100) | 23 (100) |
| Psoriasis duration [years], median (IQR) | 16.0 (12.0, 25.5) | 16.0 (10.5, 26.0) |
| Weight [kg], mean (SD) | 102.0 (23.5) | 105.1 (21.1) |
| BMI [kg/m2], mean (SD) | 33.3 (6.6) | 32.2 (5.9) |
| Previous systemic therapy | ||
| Any, n (%) | 15 (65) | 16 (70) |
| Non-biologic, n (%) | 15 (65) | 16 (70) |
| Biologic, n (%) | 2 (9) | 3 (13) |
| Psoriasis characteristics | ||
| PASI, median (IQR) | 10.9 (8.5, 15.6) | 10.6 (9.7, 15.1) |
| BSA [%], median (IQR) | 14.5 (11.0, 29.0) | 10.5 (9.2, 39.0) |
| sPGA, median (IQR) | 2.0 (2.0, 3.0) | 2.0 (2.0, 3.0) |
| DLQI, median (IQR) | 11.0 (7.5, 14.5) | 9.0 (6.5, 12.5) |
| PsA, n (%)a | 1 (4) | 3 (13) |
Data are shown for all randomized patients. Categorical variables are presented in frequencies and percentages. Numerical data are shown in medians and IQR or mean and SD. PASI ranges from 0 to 72, sPGA from 0 to 4, and DLQI from 0 to 30.
BMI, body mass index; BSA, body surface area; DLQI, dermatology life quality index; IQR, interquartile range; PASI, psoriasis area and severity index; PsA, psoriatic arthritis; SD, standard deviation; sPGA, static physician global assessment.
a
Diagnosed by a rheumatologist.